Birmingham, AL Clinical Trials Report — June 2026

For patients and healthy volunteers in Birmingham, AL, June 2026 presents a dynamic landscape of clinical research opportunities. With a total of 943 clinical trials currently recruiting across 337 research facilities, the city continues to be a significant hub for medical advancement. This month, prompt action is key for those interested in studies nearing their enrollment deadlines.

Act Now: Trials Nearing Their Close

A total of 50 clinical trials in Birmingham are scheduled to conclude within the next 90 days. This urgency is particularly relevant for individuals seeking to contribute to medical research before these opportunities close. Notably, 11 of these rapidly closing studies are still actively seeking healthy volunteers, offering a chance to participate without a specific health condition.

Patients managing specific health conditions also have limited time to join certain research initiatives. Trials focused on various cancers and other conditions are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Breast cancer (2 trials)
• Endometrial cancer (2 trials)
• Ovarian cancer (2 trials)
• Astrocytoma (2 trials)
• Glioblastoma multiforme (2 trials)
• Astrocytoma, cerebellar (1 trial)
• Brain diseases (1 trial)
• Adverse birth outcomes (1 trial)
• Behavioral variant frontotemporal dementia (bvFTD) (1 trial)
• Atrial fibrillation (AF) (1 trial)

New Research Opportunities Emerge in Birmingham

This month, Birmingham saw the opening of 21 new clinical trials, marking an increase from the 15 trials that launched in May 2026. This growth reflects a robust and expanding research environment in the city.

June brings several high-profile new trials to Birmingham, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• AstraZeneca is sponsoring a notable Phase 3 study, NCT07667803, "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This global, randomized, double-blind, parallel-group, multicenter study aims for 4,500 participants to assess the efficacy and safety of elecoglipron compared with placebo.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study targets 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron.
• Pfizer is leading two important Phase 3 studies focused on pneumococcal vaccines. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," seeks 1,200 participants to assess a new vaccine in older children.
• Kallyope Inc. is sponsoring NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter study aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study." This study aims for 2,748 participants to characterize multidisciplinary tumor board context and evaluate the impact of including patient-reported evaluations.

New trials this month are exploring a range of conditions, with the most frequent being overweight (3 trials), obesity (3 trials), hypertension (2 trials), chronic weight management (2 trials), type 2 diabetes mellitus (2 trials), chronic pain (2 trials), and pneumococcal disease (2 trials). Drug trials account for the largest share of new studies, with 13 new drug trials, followed by 6 behavioral studies and 2 biological studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 3 of the 21 new trials launched this month are actively seeking healthy volunteers. Across Birmingham, a total of 122 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Birmingham's Leading Research Facilities

Birmingham is home to prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Alabama at Birmingham (290 trials)
• University of Alabama at Birmingham Cancer Center (58 trials)
• Children's Hospital of Alabama (41 trials)
• University of Alabama Birmingham (27 trials)
• University of Alabama (25 trials)
• Research Site (23 trials)
• The University of Alabama at Birmingham (21 trials)
• Children's of Alabama (14 trials)
• UAB (12 trials)
• University of Alabama Hospital (10 trials)
• Birmingham VA Medical Center, Birmingham, AL (9 trials)
• University of Alabama - Birmingham (6 trials)

The University of Alabama at Birmingham and its associated centers clearly lead the research landscape in the city, offering a broad spectrum of studies across various medical fields.

Broadening Your Search: Nearby Options

While Birmingham offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Alabama. Cities with active trials include Auburn (2 trials), Mobile (2 trials), Daphne (1 trial), Huntsville (1 trial), Jacksonville (1 trial), and Montgomery (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 21 new trials launched this month, 18 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children. Academic institutions, particularly the University of Alabama at Birmingham (7 trials), continue to play a vital role in Birmingham's research ecosystem. Industry sponsors such as AstraZeneca (4 trials), Eli Lilly and Company (2 trials), Gasherbrum Bio, Inc. (2 trials), Kallyope Inc. (2 trials), and Pfizer (2 trials) are also driving significant research efforts, with 14 new trials sponsored by industry this month.

As we move through June, Birmingham's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and explore new treatment avenues.